    6 ADVERSE REACTIONS

  The following adverse reactions are discussed elsewhere in the labeling:



 *     Myelodysplastic≠B-OSE_Labeled_AE   syndrome≠I-OSE_Labeled_AE / Acute≠B-OSE_Labeled_AE   Myeloid≠I-OSE_Labeled_AE   Leukemia≠I-OSE_Labeled_AE  [see    Warnings and Precautions (5.1)    ]  
 *     Pneumonitis≠B-OSE_Labeled_AE  [see    Warnings and Precautions (5.2)    ]  
   *    Most common adverse reactions (>=20%) in clinical trials were  anemia≠B-OSE_Labeled_AE ,  nausea≠B-OSE_Labeled_AE ,  fatigue≠B-OSE_Labeled_AE  (including  asthenia≠B-OSE_Labeled_AE ),  vomiting≠B-OSE_Labeled_AE ,  diarrhea≠B-OSE_Labeled_AE ,  dysgeusia≠B-OSE_Labeled_AE ,  dyspepsia≠B-OSE_Labeled_AE ,  headache≠B-OSE_Labeled_AE ,  decreased≠B-OSE_Labeled_AE   appetite≠I-OSE_Labeled_AE ,  nasopharyngitis≠B-OSE_Labeled_AE / pharyngitis≠B-OSE_Labeled_AE / URI≠B-OSE_Labeled_AE ,  cough≠B-OSE_Labeled_AE ,  arthralgia≠B-OSE_Labeled_AE / musculoskeletal≠B-OSE_Labeled_AE   pain≠I-OSE_Labeled_AE ,  myalgia≠B-OSE_Labeled_AE ,  back≠B-OSE_Labeled_AE   pain≠I-OSE_Labeled_AE ,  dermatitis≠B-OSE_Labeled_AE / rash≠B-OSE_Labeled_AE  and  abdominal≠B-OSE_Labeled_AE   pain≠I-OSE_Labeled_AE /discomfort. (  6.1  ) 
 *    Most common laboratory abnormalities (>=25%) were  increase≠B-OSE_Labeled_AE  in  creatinine≠I-OSE_Labeled_AE ,  mean≠B-OSE_Labeled_AE   corpuscular≠I-OSE_Labeled_AE   volume≠I-OSE_Labeled_AE   elevation≠I-OSE_Labeled_AE ,  decrease≠B-OSE_Labeled_AE   in≠I-OSE_Labeled_AE   hemoglobin≠I-OSE_Labeled_AE ,  decrease≠B-OSE_Labeled_AE   in≠I-OSE_Labeled_AE   lymphocytes≠I-OSE_Labeled_AE ,  decrease≠B-OSE_Labeled_AE   in≠I-OSE_Labeled_AE   absolute≠I-OSE_Labeled_AE   neutrophil≠I-OSE_Labeled_AE   count≠I-OSE_Labeled_AE , and  decrease≠B-OSE_Labeled_AE   in≠I-OSE_Labeled_AE   platelets≠I-OSE_Labeled_AE . (  6.1  ) 
      EXCERPT:   To report SUSPECTED ADVERSE REACTIONS, contact AstraZeneca at 1-800-236-9933 or FDA at 1-800-FDA-1088 or  www.fda.gov/medwatch.  
 

 

  6.1 Clinical Trial Experience

  Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.



 Lynparza 400 mg twice daily as monotherapy, has been studied in 300 patients with g   BRCA≠B-Not_AE_Candidate    -≠I-Not_AE_Candidate  mutated≠I-Not_AE_Candidate   advanced≠I-Not_AE_Candidate   ovarian≠I-Not_AE_Candidate   cancer≠I-Not_AE_Candidate , and 223 of these patients had received 3 or more prior lines of chemotherapy.



 In the 223 patients with  g≠B-Not_AE_Candidate    BRCA≠I-Not_AE_Candidate    -≠I-Not_AE_Candidate  mutated≠I-Not_AE_Candidate   ovarian≠I-Not_AE_Candidate   cancer≠I-Not_AE_Candidate  who received 3 or more prior lines of chemotherapy (including 137 patients in Study 1 with measureable disease)  [see      Clinical Studies (14)      ]  , adverse reactions led to dose interruption in 40% of patients, dose reduction in 4%, and discontinuation in 7%. There were 8 (4%) patients with adverse reactions leading to  death≠B-NonOSE_AE , two were attributed to  acute≠B-OSE_Labeled_AE   leukemia≠I-OSE_Labeled_AE , and one each was attributed to  COPD≠B-OSE_Labeled_AE ,  cerebrovascular≠B-OSE_Labeled_AE   accident≠I-OSE_Labeled_AE ,  intestinal≠B-OSE_Labeled_AE   perforation≠I-OSE_Labeled_AE ,  pulmonary≠B-OSE_Labeled_AE   embolism≠I-OSE_Labeled_AE ,  sepsis≠B-OSE_Labeled_AE , and suture rupture. Table 1 presents the frequency of adverse reactions reported in >=20% of 223 patients (in 6 studies) with  g≠B-Not_AE_Candidate    BRCA≠I-Not_AE_Candidate    -≠I-Not_AE_Candidate  mutated≠I-Not_AE_Candidate   advanced≠I-Not_AE_Candidate   ovarian≠I-Not_AE_Candidate   cancer≠I-Not_AE_Candidate  who had received 3 or more prior lines of chemotherapy who were treated with Lynparza 400 mg twice daily. The median exposure to Lynparza in these patients was 158 days.



 Table 1 Adverse Reactions Reported in >=20% of Patients with gBRCA-Mutated Advanced Ovarian Cancer Receiving Lynparza 
                                                       3 or more lines of prior chemotherapy    
  Adverse Reaction                                     Grades 1-4  N=223  %    Grades 3-4  N=223  %    
   Blood≠B-NonOSE_AE   and≠I-NonOSE_AE   Lymphatic≠I-NonOSE_AE   disorders≠I-NonOSE_AE                         
                                                       Anemia≠B-OSE_Labeled_AE                                               
                                                                                                            34                      18                     
   Gastrointestinal≠B-NonOSE_AE   disorders≠I-NonOSE_AE                            
                                                       Abdominal≠B-OSE_Labeled_AE   pain≠I-OSE_Labeled_AE /discomfort                           
                                                                                                            43                      8                      
                                                       Decreased≠B-OSE_Labeled_AE   appetite≠I-OSE_Labeled_AE                                   
                                                                                                            22                      1                      
                                                       Nausea≠B-OSE_Labeled_AE                                               
                                                                                                            64                      3                      
                                                       Vomiting≠B-OSE_Labeled_AE                                             
                                                                                                            43                      4                      
                                                       Diarrhea≠B-OSE_Labeled_AE                                             
                                                                                                            31                      1                      
                                                       Dyspepsia≠B-OSE_Labeled_AE                                            
                                                                                                            25                      0                      
   General≠B-NonOSE_AE   disorders≠I-NonOSE_AE                                     
                                                       Fatigue≠B-OSE_Labeled_AE / asthenia≠B-OSE_Labeled_AE                                     
                                                                                                            66                      8                      
   Infections≠B-NonOSE_AE   and≠I-NonOSE_AE   infestations≠I-NonOSE_AE                                                                          
                                                       Nasopharyngitis≠B-OSE_Labeled_AE / URI≠B-OSE_Labeled_AE                                  
                                                                                                            26                      0                      
   Musculoskeletal≠B-NonOSE_AE   and≠I-NonOSE_AE   Connective≠I-NonOSE_AE   Tissue≠I-NonOSE_AE   disorders≠I-NonOSE_AE                                                      
                                                       Arthralgia≠B-OSE_Labeled_AE / musculoskeletal≠B-OSE_Labeled_AE   pain≠I-OSE_Labeled_AE                      
                                                                                                            21                      0                      
                                                       Myalgia≠B-OSE_Labeled_AE                                              
                                                                                                            22                      0                      
         Table 2 presents the frequency of  abnormal≠B-NonOSE_AE   laboratory≠I-NonOSE_AE   findings≠I-NonOSE_AE  in the 223 patients with  g≠B-Not_AE_Candidate    BRCA≠I-Not_AE_Candidate    -≠I-Not_AE_Candidate  mutated≠I-Not_AE_Candidate   advanced≠I-Not_AE_Candidate   ovarian≠I-Not_AE_Candidate   cancer≠I-Not_AE_Candidate  who had received three or more prior lines of chemotherapy receiving Lynparza 400 mg twice daily.
 

 Table 2 Laboratory Abnormalities Reported in Patients with gBRCA-Mutated Advanced Ovarian Cancer Receiving Lynparza 
  Laboratory Parameter1                                3 or more lines of prior chemotherapy    
  Grades 1-4  N=223  %                                 Grades 3-4  N=223  %    
   Decrease≠B-OSE_Labeled_AE   in≠I-OSE_Labeled_AE   hemoglobin≠I-OSE_Labeled_AE  ( anemia≠B-OSE_Labeled_AE )                      90                      15                     
   Decrease≠B-OSE_Labeled_AE   in≠I-OSE_Labeled_AE   absolute≠I-OSE_Labeled_AE   neutrophil≠I-OSE_Labeled_AE   count≠I-OSE_Labeled_AE  ( neutropenia≠B-OSE_Labeled_AE )    25                      7                      
   Decrease≠B-OSE_Labeled_AE   in≠I-OSE_Labeled_AE   platelets≠I-OSE_Labeled_AE  ( thrombocytopenia≠B-OSE_Labeled_AE )             30                      3                      
   Decrease≠B-OSE_Labeled_AE   in≠I-OSE_Labeled_AE   lymphocytes≠I-OSE_Labeled_AE  ( lymphopenia≠B-OSE_Labeled_AE )                56                      17                     
   Mean≠B-OSE_Labeled_AE   corpuscular≠I-OSE_Labeled_AE   volume≠I-OSE_Labeled_AE   elevation≠I-OSE_Labeled_AE                     57                      -                      
   Increase≠B-OSE_Labeled_AE   in≠I-OSE_Labeled_AE   creatinine≠I-OSE_Labeled_AE                                30                      2                      
         The following adverse reactions and  laboratory≠B-NonOSE_AE   abnormalities≠I-NonOSE_AE  have been identified in >=10 to <20% of the 223 patients receiving Lynparza and not included in the table:  cough≠B-OSE_Labeled_AE ,  constipation≠B-OSE_Labeled_AE ,  dysgeusia≠B-OSE_Labeled_AE ,  peripheral≠B-OSE_Labeled_AE   edema≠I-OSE_Labeled_AE ,  back≠B-OSE_Labeled_AE   pain≠I-OSE_Labeled_AE ,  dizziness≠B-OSE_Labeled_AE ,  headache≠B-OSE_Labeled_AE ,  urinary≠B-OSE_Labeled_AE   tract≠I-OSE_Labeled_AE   infection≠I-OSE_Labeled_AE ,  dyspnea≠B-OSE_Labeled_AE , and  rash≠B-OSE_Labeled_AE . The following adverse reactions and  laboratory≠B-NonOSE_AE   abnormalities≠I-NonOSE_AE  have been identified in >=1 to <10% of the 223 patients receiving Lynparza and not included in the table:  leukopenia≠B-OSE_Labeled_AE ,  stomatitis≠B-OSE_Labeled_AE ,  peripheral≠B-OSE_Labeled_AE   neuropathy≠I-OSE_Labeled_AE ,  pyrexia≠B-OSE_Labeled_AE ,  hypomagnesemia≠B-OSE_Labeled_AE ,  hyperglycemia≠B-OSE_Labeled_AE ,  anxiety≠B-OSE_Labeled_AE ,  depression≠B-OSE_Labeled_AE ,  insomnia≠B-OSE_Labeled_AE ,  dysuria≠B-OSE_Labeled_AE ,  urinary≠B-OSE_Labeled_AE   incontinence≠I-OSE_Labeled_AE ,  vulvovaginal≠B-OSE_Labeled_AE   disorder≠I-OSE_Labeled_AE ,  dry≠B-OSE_Labeled_AE   skin≠I-OSE_Labeled_AE /  eczema≠B-OSE_Labeled_AE ,  pruritis≠B-OSE_Labeled_AE ,  hypertension≠B-OSE_Labeled_AE ,  venous≠B-OSE_Labeled_AE   thrombosis≠I-OSE_Labeled_AE  (including  pulmonary≠B-OSE_Labeled_AE   embolism≠I-OSE_Labeled_AE ), and  hot≠B-OSE_Labeled_AE   flush≠I-OSE_Labeled_AE .
 

 Table 3 presents adverse reactions reported in >=20% of patients from a randomized trial of Lynparza 400 mg twice daily as maintenance monotherapy compared to placebo in patients with platinum sensitive, relapsed, high-grade serous  ovarian≠B-Not_AE_Candidate   cancer≠I-Not_AE_Candidate  following treatment with 2 or more platinum-containing regimens. Table 4 presents the  laboratory≠B-NonOSE_AE   abnormalities≠I-NonOSE_AE  in patients from this randomized trial. Of the 96 patients with  g≠B-Not_AE_Candidate    BRCA≠I-Not_AE_Candidate    -≠I-Not_AE_Candidate  mutation≠I-Not_AE_Candidate , 53 received Lynparza, and 43 received placebo. The median duration on treatment with Lynparza was 11.1 months for patients with a  g≠B-Not_AE_Candidate    BRCA≠I-Not_AE_Candidate    mutation≠I-Not_AE_Candidate  compared to 4.4 months for patients with  g≠B-Not_AE_Candidate    BRCA≠I-Not_AE_Candidate    mutation≠I-Not_AE_Candidate  on placebo.



 Adverse reactions led to dose interruptions in 26% of those receiving Lynparza and 7% of those receiving placebo; dose reductions in 15% of Lynparza and 5% of placebo patients; and discontinuation in 9% of Lynparza and 0% in placebo patients. One (2%) patient on Lynparza  died≠B-NonOSE_AE  as a result of an adverse reaction.



 Table 3 Adverse Reactions Reported in >=20% of Patients with gBRCA-Mutated Ovarian Cancer in the Randomized Trial 
  Adverse Reactions                        Lynparza  N=53    Placebo  N=43    
                                           Grades 1-4  %    Grades 3-4  %    Grades 1-4  %      Grades 3-4  %     
   Blood≠B-NonOSE_AE   and≠I-NonOSE_AE   Lymphatic≠I-NonOSE_AE   disorders≠I-NonOSE_AE                                                                                  
                                           Anemia≠B-OSE_Labeled_AE                                   
                                                                                    25              4               7                  2                 
   Gastrointestinal≠B-NonOSE_AE   disorders≠I-NonOSE_AE                
                                           Abdominal≠B-OSE_Labeled_AE   pain≠I-OSE_Labeled_AE /discomfort               
                                                                                    47              0               58                 2                 
                                           Decreased≠B-OSE_Labeled_AE   appetite≠I-OSE_Labeled_AE                       
                                                                                    25              0               14                 0                 
                                           Nausea≠B-OSE_Labeled_AE                                   
                                                                                    75              2               37                 0                 
                                           Vomiting≠B-OSE_Labeled_AE                                 
                                                                                    32              4               9                  0                 
                                           Diarrhea≠B-OSE_Labeled_AE                                 
                                                                                    28              4               21                 2                 
                                           Dyspepsia≠B-OSE_Labeled_AE                                
                                                                                    25              0               14                 0                 
                                           Dysgeusia≠B-OSE_Labeled_AE                                
                                                                                    21              0               9                  0                 
   General≠B-NonOSE_AE   disorders≠I-NonOSE_AE                         
                                           Fatigue≠B-OSE_Labeled_AE  (including  asthenia≠B-OSE_Labeled_AE ,  lethargy≠B-OSE_Labeled_AE )  
                                                                                    68              6               53                 2                 
   Infections≠B-NonOSE_AE   and≠I-NonOSE_AE   infestations≠I-NonOSE_AE                                                                                    
                                           Nasopharyngitis≠B-OSE_Labeled_AE / Pharyngitis≠B-OSE_Labeled_AE / URI≠B-OSE_Labeled_AE          
                                                                                    43              0               16                 0                 
   Musculoskeletal≠B-NonOSE_AE   and≠I-NonOSE_AE   Connective≠I-NonOSE_AE   tissue≠I-NonOSE_AE   disorders≠I-NonOSE_AE                                                                          
                                           Arthralgia≠B-OSE_Labeled_AE / Musculoskeletal≠B-OSE_Labeled_AE   pain≠I-OSE_Labeled_AE          
                                                                                                   32             
                                                 4              
                                                    21                
                                                         0                
                                      
                                           Myalgia≠B-OSE_Labeled_AE                                  
                                                                                                   25             
                                                 2              
                                                    12                
                                                         0                
                                      
                                           Back≠B-OSE_Labeled_AE   pain≠I-OSE_Labeled_AE                                
                                                                                                   25             
                                                 6              
                                                    21                
                                                         0                
                                      
   Nervous≠B-NonOSE_AE   system≠I-NonOSE_AE   disorder≠I-NonOSE_AE                   
                                           Headache≠B-OSE_Labeled_AE                                 
                                                                                    25              0               19                 2                 
   Respiratory≠B-NonOSE_AE  ,≠I-NonOSE_AE   Thoracic≠I-NonOSE_AE  ,≠I-NonOSE_AE   Mediastinal≠I-NonOSE_AE   disorders≠I-NonOSE_AE                                                                          
                                           Cough≠B-OSE_Labeled_AE                                    
                                                                                    21              0               14                 0                 
   Skin≠B-NonOSE_AE   and≠I-NonOSE_AE   Subcutaneous≠I-NonOSE_AE   Tissue≠I-NonOSE_AE                                                                                   
                                           Dermatitis≠B-OSE_Labeled_AE / Rash≠B-OSE_Labeled_AE                          
                                                                                    25              0               14                 0                 
          Table 4 Laboratory Abnormalities in Patients with gBRCA-Mutated Ovarian Cancer in the Randomized Trial 
  Laboratory parameter1                    Lynparza  N=53    Placebo  N=43    
                                           Grades 1-4  %    Grades 3-4  %    Grades 1-4  %      Grades 3-4  %     
   Decrease≠B-OSE_Labeled_AE   in≠I-OSE_Labeled_AE   hemoglobin≠I-OSE_Labeled_AE                    85              8               58                 2                 
   Decrease≠B-OSE_Labeled_AE   in≠I-OSE_Labeled_AE   absolute≠I-OSE_Labeled_AE   neutrophil≠I-OSE_Labeled_AE   count≠I-OSE_Labeled_AE     32              8               23                 0                 
   Decrease≠B-OSE_Labeled_AE   in≠I-OSE_Labeled_AE   platelets≠I-OSE_Labeled_AE                     26              6               19                 0                 
   Mean≠B-OSE_Labeled_AE   corpuscular≠I-OSE_Labeled_AE   volume≠I-OSE_Labeled_AE   elevation≠I-OSE_Labeled_AE         85              -               44                 -                 
   Increase≠B-OSE_Labeled_AE   in≠I-OSE_Labeled_AE   creatinine≠I-OSE_Labeled_AE Patients were allowed to enter clinical studies with laboratory values of CTCAE Grade 1.    26              0               5                  0                 
